Tag: Bivalirudin

With heart disease being the world's leading cause of death, anticoagulants are more important than ever [1.5.2]. Direct thrombin inhibitors (DTIs) represent a vital class of these drugs. Understanding **how are direct thrombin inhibitors administered**—primarily orally or intravenously—is key to their safe and effective use [1.2.1].

According to research, blood clots are a major health risk, with millions affected by conditions like deep vein thrombosis (DVT), and anticoagulants play a crucial role in prevention and treatment. An important class of these drugs includes direct thrombin inhibitors (DTIs), but many people still ask, "Which of the following is considered a direct thrombin inhibitor?". This article explains how DTIs work and lists specific examples.

Millions of people worldwide require anticoagulant therapy for conditions like atrial fibrillation and deep vein thrombosis. Knowing **what drugs are direct thrombin inhibitors** is crucial, as these powerful medications offer distinct advantages over traditional anticoagulants by directly targeting the key clotting enzyme, thrombin.

As a rapid and predictable anticoagulant, bivalirudin's exclusive route of administration is intravenous (IV). This precise delivery method is essential for its use in critical cardiovascular procedures, such as percutaneous coronary intervention (PCI) and the management of heparin-induced thrombocytopenia (HIT).

First approved by the FDA in 2000, **Angiomax** (bivalirudin) is a potent anticoagulant used to prevent blood clots during cardiac procedures, including percutaneous coronary intervention (PCI). It is particularly valuable for patients with heparin-induced thrombocytopenia (HIT) who require PCI.